Hedge Funds

Esperion settles with troubled Durus


In January, Esperion Therapeutics settled the civil suit filed in Connecticut six months ago against the Durus Life Sciences Master Fund, which recently agreed to pay $32 million.

The case comes only a matter of weeks after Esperion agreed to be acquired by pharmaceutical giant Pfizer. The deal suggests that Esperion did not get the upper hand in the dispute with Scott Sacane's Durus which emerged in August.

In exchange for the $32 million offered in mid-January, Durus expects Esperion to acknowledge the appropriateness of the fund group's tender offer on Esperion stock, for which Pfizer was willing to